Piper Sandler analyst David Amsellem reiterated an Overweight rating and $258.00 price target on Axsome Therapeutics (NASDAQ: AXSM).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments